Bone Biologics completed a $5.75 million funding round.
Here are three things to know:
1. The funds will be used for the development and synthesis of a potential bone graft substitute product focused on bone regeneration in spinal fusion procedures.
2. The lead product, Nell-1, has shown clinical potential in the laboratory and in animal testing.
3. The funding round included Musculoskeletal Transplant Foundation, Orthofix and Hankey Capital.